Human induced pluripotent stem cells (iPSCs) are being used in regenerative medicine to provide human regenerative cells (tissues), as well as in drug development for compound screening or etiology elucidation, replacing traditional model animals. On the other hand, glycobiology research on these human iPSCs is lagging. We attempted to create a glycan recognition antibody by immunizing mice with human iPSCs and successfully developed R-10G [1], R-17F [2, 3], and, then, R-6C, R-13E [4]. R-10G recognizes low-sulfated keratan sulfate, which could not be detected by conventional keratan sulfate recognition antibodies. The R-10G epitope is characteristically expressed on a high molecular weight mucin-like protein called podocalyxin contained in human iPSCs. R-17F mainly recognizes a glycolipid in which lacto-N-fucopentaose I is bound to ceramide. R-10G, R-17F are IgG1 antibodies, and R-6C, R-13E are IgM. The epitope structures of these antibodies are shown (Fig. 13.1) .

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Glycan Recognition Marker Antibody Developed Using Human iPS Cells as an Antigen

  • Toshisuke Kawasaki

摘要

Human induced pluripotent stem cells (iPSCs) are being used in regenerative medicine to provide human regenerative cells (tissues), as well as in drug development for compound screening or etiology elucidation, replacing traditional model animals. On the other hand, glycobiology research on these human iPSCs is lagging. We attempted to create a glycan recognition antibody by immunizing mice with human iPSCs and successfully developed R-10G [1], R-17F [2, 3], and, then, R-6C, R-13E [4]. R-10G recognizes low-sulfated keratan sulfate, which could not be detected by conventional keratan sulfate recognition antibodies. The R-10G epitope is characteristically expressed on a high molecular weight mucin-like protein called podocalyxin contained in human iPSCs. R-17F mainly recognizes a glycolipid in which lacto-N-fucopentaose I is bound to ceramide. R-10G, R-17F are IgG1 antibodies, and R-6C, R-13E are IgM. The epitope structures of these antibodies are shown (Fig. 13.1) .